Drugs / TF(c)-KLH conjugate vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003819 | Jun 1998 → Mar 2009 | prostate cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TF(c)-KLH conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003819 ↗ |
| Known as | Thompson-Friedenreich [TF(c)]-KLH Conjugate | “Vaccination of Prostate Cancer Patients With Thompson-Friedenreich [TF(c)]-KLH Conjugate Plus the Immunological Adjuvant QS21: A Trial Comparing TF(c)-KLH Doses” NCT00003819 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00003819 ↗ |
| Modality | Vaccine | “TF(c)-KLH conjugate vaccine” NCT00003819 ↗ |
| Route | Subcutaneous | “Patients receive TF(c)-KLH conjugate with adjuvant QS21 subcutaneously weekly for 3 weeks, then once during weeks 7 and 19.” NCT00003819 ↗ |